Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Jaguar Health Begins IIT for Crofelemer in Short Bowel Syndrome (SBS-IF)
Details : Mytesi (crofelemer) is a CFTR/CaCC inhibitor small molecule drug, which is being evaluated for the treatment of short bowel syndrome with intestinal failure.
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2024
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crofelemer
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Jaguar Submits Orphan Drug Designation Application for Crofelemer
Details : Crofelemer is a plant-based drug extracted from red bark sap, being developed for treating moderate-to-severe diarrhea from various infections, including Vibrio cholerae.
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : Crofelemer
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Jaguar Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Jaguar Submits Clinical Trial Applications for Crofelemer in Rare Diseases
Details : The company submitted a CTA to the Italian and German health authorities to initiate a phase 2 trial of Mytesi (crofelemer) for the treatment of short bowel syndrome with intestinal failure in adults.
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 05, 2024
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Jaguar Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Jaguar Health Submits Breast Cancer Therapy Diarrhea Impact Study Abstract
Details : Mytesi (crofelemer) is a CFTR/CaCC inhibitor small molecule drug administered orally as a delayed release tablet, for prophylaxis of diarrhea in cancer patients.
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 10, 2024
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crofelemer
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mytesi (crofelemer) is a CFTR/CaCC inhibitor small molecule drug administered orally as a delayed release tablet, for prophylaxis of diarrhea in cancer patients.
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 12, 2023
Lead Product(s) : Crofelemer
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crofelemer
Therapeutic Area : Rare Diseases and Disorders
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mytesi (crofelemer) powder for oral solution inhibits both cAMP-stimulated CFTR chloride ion channel and the CaCC at the luminal membrane of enterocytes, which being investigated for the treatment of microvillus inclusion disease.
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 08, 2023
Lead Product(s) : Crofelemer
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crofelemer
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Quadri Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Napo grants Quadri Pharma exclusive promotional, commercialization, and distribution rights for a powder formulation of Mytesi (crofelemer), the only oral FDA-approved prescription drug under botanical guidance, for oral solution.
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 11, 2023
Lead Product(s) : Crofelemer
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Quadri Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Crofelemer
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Oasis Capital
Deal Size : $2.3 million
Deal Type : Agreement
Details : Oasis agreed to purchase additional accounts receivable of the Company related to the sales of the Company's Mytesi® drug product to Cardinal Health for the period of August 11, 2020 through September 3, 2020.
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 09, 2020
Lead Product(s) : Crofelemer
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Oasis Capital
Deal Size : $2.3 million
Deal Type : Agreement
Lead Product(s) : NP-500
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Atlas Sciences
Deal Size : $1.5 million
Deal Type : Licensing Agreement
Details : Under the the license, Jaguar has to initiate Phase 2 study of NP-500 under an investigational new drug application with the U.S. FDA or an IND-equivalent dossier within six months of April 15, 2020.
Product Name : NP-500
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 16, 2020
Lead Product(s) : NP-500
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Atlas Sciences
Deal Size : $1.5 million
Deal Type : Licensing Agreement